Science (New York, N.Y.), 12 August 2011, Vol.333(6044), pp.843-50
Current flu vaccines provide only limited coverage against seasonal strains of influenza viruses. The identification of V(H)1-69 antibodies that broadly neutralize almost all influenza A group 1 viruses constituted a breakthrough in the influenza field. Here, we report the isolation and characterization of a human monoclonal antibody CR8020 with broad neutralizing activity against most group 2 viruses, including H3N2 and H7N7, which cause severe human infection. The crystal structure of Fab CR8020 with the 1968 pandemic H3 hemagglutinin (HA) reveals a highly conserved epitope in the HA stalk distinct from the epitope recognized by the V(H)1-69 group 1 antibodies. Thus, a cocktail of two antibodies may be sufficient to neutralize most influenza A subtypes and, hence, enable development of a universal flu vaccine and broad-spectrum antibody therapies.
Antibodies, Monoclonal -- Immunology ; Antibodies, Neutralizing -- Immunology ; Antibodies, Viral -- Immunology ; Antigens, Viral -- Immunology ; Hemagglutinin Glycoproteins, Influenza Virus -- Immunology ; Influenza A Virus -- Immunology
View this record in MEDLINE/PubMed